Aug. 26 Repair-Stem-Cell-stdy
BANGKOK, Aug. 26 /PRNewswire/ -- The Repair Stem Cell Institute LLC
(RSCI; http://www.RepairSemCells.org) reported today that Stanford University
School of Medicine's recent discovery there may be limitations to the
effectiveness of human therapies derived from embryonic stem cells (ESC)
because the cells injected in mice stimulated the kind of immune rejection
seen with transplanted organs clearly delivers a blow to proponents of
embryonic stem cell research who continue to ballyhoo the promise of ESC when
in effect, as the Stanford study showed, the transplanted stem cells were dead
within about seven to 10 days.
According to Don Margolis (donmargolis@gmail.com; 214.556.6377), founder
and chairman of the RSCI, "The new Stanford findings further confirm the
futility of embryonics in human therapy despite what proponents of human ESC
research have been promising, that transplanted ESC can mature into several
different types of tissue. Those cells could not survive in the mouse,
suggesting the same would likely occur in a patient." He noted a statement
from Stanford radiologist Dr. Joseph Wu, part of the research team: "I think
there's some promise [to human ESCs] but you don't want to be foolish and say
these cells are going to cure things in the next five years."
Mr. Margolis said in addition to the Stanford findings presenting
difficulties to one day permit human trials, the U.S. Food and Drug
Administration has not approved "the injection of ESCs into patients because
they also have the potential to become cancerous."
He also said, "With over 100 diseases already being treated with Repair
Stem Cells by the world's finest doctors, the need for further ESC research
merely to add to 10 years of futility is called into question."
Visit http://www.RepairStemCells.org/StemCellTreatmentCenters.php for
RSCI's global listing of stem cell treatment centers and the practitioners
meeting its standards of excellence who are already treating those 100+
medical conditions with success.
About the RSCI
The Repair Stem Cell Institute LLC is a global independent public service
company dedicated to bringing the news about Repair Stem Cell treatments to
the public. The RSCI was founded in April 2008 and is based in Bangkok with
administrative headquarters in Dallas and a communications, government and
public affairs office in Washington.
SOURCE The Repair Stem Cell Institute LLC
